<DOC>
	<DOCNO>NCT02457247</DOCNO>
	<brief_summary>The purpose study compare preference Calcichew D3 500/400 ( contain 500 mg calcium 400 IU vitamin D ) Adcal-D3 600/400 ( contain 600 mg calcium 400 IU vitamin D ) Test Group 1 , compare Calcichew D3 500/800 ( contain 500 mg calcium 800 IU vitamin D ) Kalcipos-D 500/800 ( contain 500 mg calcium 800 IU vitamin D ) Test Group 2 .</brief_summary>
	<brief_title>Calcichew D3 Preference Study Participants Eligible Calcium Vitamin D Supplementation .</brief_title>
	<detailed_description>The drug test study call Calcichew D3 new formulation : Calcichew D3 500/400 Calcichew D3 500/800 . Calcichew D3 500/400 Calcichew D3 500/800 test treat prevent calcium vitamin D deficiency . Calcichew D3 500/400 compare Adcal-D3 600/400 prescribe clinical practice Calcichew D3 500/800 compare Kalcipos-D 500/800 prescribe clinical practice . This Crossover study enroll approximately 276 patient equally divide two test group ( 138 patient ) . Within test group , participant randomly assign ( chance , like flip coin ) one two treatment sequence , describe . Test Group 1 : - Calcichew D3 500/400 ( contain 500 mg calcium 400 IU vitamin D ) chewable tablet - Adcal-D3 600/400 ( contain 600 mg calcium 400 IU vitamin D ) chewable tablet Test Group 2 : - Calcichew D3 500/800 ( contain 500 mg calcium 800 IU vitamin D ) chewable tablet - Kalcipos-D 500/800 ( contain 500 mg calcium 800 IU vitamin D ) chewable tablet Participants Test Group 1 take either Calcichew D3 500/400 Adcal-D3 600/400 14 day crossover take either Calcichew D3 500/400 Adcal-D3 600/400 treatment 14 day . Participants Test Group 2 take either Calcichew D3 500/800 Kalcipos-D 600/400 14 day crossover take either Calcichew D3 500/800 Kalcipos-D treatment 14 day . This multi-center trial conduct In United Kingdom Germany . The overall time participate study 28 day . Participants make multiple visit clinic include final visit assessment Day 28 .</detailed_description>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . Signs date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is eligible currently receive treatment calcium vitamin D supplement determine treat clinician accordance local treatment guideline . 4 . Eligible participant either : 1 . Aged 65 year old require calcium vitamin D supplementation prevention treatment deficiency , 2 . Aged 18 year old require calcium vitamin D adjunct specific osteoporosis treatment participant risk calcium vitamin D deficiency . 5 . Is male female . 6 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study , 12 week last dose study medication . 1 . Has receive Calcichew D3 , AdcalD3 ( participant Test Group 1 ) KalciposD ( participant Test Group 2 ) within 6 month prior first dose study medication . 2 . Has receive investigational compound within 30 day prior Screening . 3 . Has disease and/or condition result hypercalcaemia and/or hypercalciuria study drug contraindicate e.g . ZollingerEllison syndrome , nephrolithiasis . 4 . Has contraindication list correspond Summary Product Characteristics ( SPC ) study drug participant may receive depend Test Group : Calcichew D3 AdcalD3 ( participant Test Group 1 ) ; Calcichew D3 KalciposD ( participant Test Group 2 ) . 5 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 6 . Has history hypersensitivity allergy active substance excipients investigational product . 7 . Has history know fructose intolerance , glucosegalactose malabsorption sucraseisomaltase insufficiency . 8 . If female , participant pregnant lactate intend become pregnant , , within 12 week participate study ; intend donate ova time period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>